Second Genome

Second Genome, a venture-backed Bay Area based life sciences company, is committed to improving the quality of human health through microbiome-based personalized medicine. Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders. Working with academic and commercial collaborators, Second Genome is developing novel diagnostic tools and therapies for unmet needs in gastrointestinal disorders. The company has established a pipeline of microbiome modulators that impact infection, inflammation, and metabolic diseases. Second Genome entered into the first ever big pharmaceutical partnership focused on microbiome drug discovery with Janssen Biotech, Inc. in June 2013 for new treatments for ulcerative colitis.
Company Growth (employees)
Type
Private
HQ
South San Francisco, US
Founded
2009
Size (employees)
40 (est)-6%
Second Genome was founded in 2009 and is headquartered in South San Francisco, US

Key People at Second Genome

Peter DiLaura

Peter DiLaura

President & CEO
Todd DeSantis

Todd DeSantis

Co-Founder & Head of Bioinformatics
Janet A. Warrington

Janet A. Warrington

Co-Founder & SVP, Platform Technologies
Peter S. DiStefano

Peter S. DiStefano

Sr VP Research & Development
Mohan Iyer

Mohan Iyer

SVP Corporate Development

Second Genome Office Locations

Second Genome has office in South San Francisco
South San Francisco, US

Second Genome Metrics

Second Genome Summary

We estimate that Second Genome's latest funding round in July 2016 was $8.4 m. In total, Second Genome has raised $70 m

Second Genome Online Presence

Second Genome News

Second Genome Company Life

You may also be interested in